NEU 0.98% $19.50 neuren pharmaceuticals limited

Ann: Neuren presents at Rettsyndrome.org 2016 Research Symposium-NEU.AX, page-4

  1. 65 Posts.
    lightbulb Created with Sketch. 4
    I wonder what the outcome would have been had the efficacy assessment been based on mba alone. Would that constitute proof and we would be progressing rapidly to commercialisation?

    If they have got fda signed off on mba as the efficacy criteria, as could be assumed from their comments, surely NEU just has to repeat the same outcome and we are in business. I am pretty optimistic.
    Last edited by McKracken: 28/06/16
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$19.50
Change
0.190(0.98%)
Mkt cap ! $2.490B
Open High Low Value Volume
$19.39 $19.98 $19.38 $7.285M 370.6K

Buyers (Bids)

No. Vol. Price($)
11 7318 $19.50
 

Sellers (Offers)

Price($) Vol. No.
$19.52 593 1
View Market Depth
Last trade - 16.10pm 14/06/2024 (20 minute delay) ?
Last
$19.55
  Change
0.190 ( 0.83 %)
Open High Low Volume
$19.41 $19.97 $19.39 83274
Last updated 15.59pm 14/06/2024 ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.